Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNMD 
CONMED Corporation (CNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CNMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $61
1 Year Target Price $61
| 0 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.41% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.68B USD | Price to earnings Ratio 15.36 | 1Y Target Price 61 |
Price to earnings Ratio 15.36 | 1Y Target Price 61 | ||
Volume (30-day avg) 6 | Beta 1.17 | 52 Weeks Range 45.83 - 77.23 | Updated Date 08/29/2025 |
52 Weeks Range 45.83 - 77.23 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 1.49% | Basic EPS (TTM) 3.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.31% | Operating Margin (TTM) 10.62% |
Management Effectiveness
Return on Assets (TTM) 4.03% | Return on Equity (TTM) 11.69% |
Valuation
Trailing PE 15.36 | Forward PE 27.03 | Enterprise Value 2511100161 | Price to Sales(TTM) 1.27 |
Enterprise Value 2511100161 | Price to Sales(TTM) 1.27 | ||
Enterprise Value to Revenue 1.89 | Enterprise Value to EBITDA 10.26 | Shares Outstanding 30955000 | Shares Floating 30676368 |
Shares Outstanding 30955000 | Shares Floating 30676368 | ||
Percent Insiders 0.58 | Percent Institutions 114.89 |
Upturn AI SWOT
CONMED Corporation
Company Overview
History and Background
CONMED Corporation was founded in 1970 as Consolidated Medical Equipment, later shortening its name to CONMED. Initially focused on electrosurgical products, the company expanded its offerings through organic growth and acquisitions, becoming a global medical technology company specializing in surgical devices and equipment.
Core Business Areas
- Orthopedics: Develops and markets a broad range of orthopedic surgery products, including arthroscopic, hip, knee, and extremity reconstruction, sports medicine, and tissue regeneration.
- General Surgery: Provides a comprehensive suite of products for general surgery, including advanced surgical energy, endosurgery, and patient care products.
Leadership and Structure
CONMED is led by a board of directors and a senior management team. The organizational structure is divided by business segments (Orthopedics and General Surgery) and functional areas such as sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- Advanced Surgical Energy: Includes electrosurgical generators, smoke evacuation systems, and related accessories. This segment competes with Medtronic and Ethicon. Revenue from surgical devices contributes significantly to their overall revenue. There is no reliable data on revenue from this product line.
- Competitors: Medtronic (MDT), Ethicon (JNJ)
- Arthroscopic Solutions: Products for minimally invasive joint procedures, including arthroscopic shavers, fluid management systems, and implants. Competitors include Stryker and Smith & Nephew. Market share is competitive, with CONMED holding a significant presence.
- Competitors: Stryker (SYK), Smith & Nephew (SNN)
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, stringent regulatory oversight, and increasing demand driven by an aging population and rising healthcare expenditures. Competition is intense, with companies vying for market share through product differentiation and strategic partnerships.
Positioning
CONMED is a mid-sized player in the medical device market, focusing on niche areas within orthopedics and general surgery. Its competitive advantages include a strong product portfolio, established customer relationships, and a commitment to innovation.
Total Addressable Market (TAM)
The total addressable market (TAM) for CONMED's products spans orthopedics and general surgery, estimated to be in the tens of billions of dollars. CONMED, with its focus on specialized surgical solutions, captures a portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong brand reputation in specialized surgical areas
- Diverse product portfolio
- Established distribution network
- History of innovation
- Dedicated customer base
Weaknesses
- Smaller market capitalization compared to major competitors
- Limited international presence compared to global giants
- Dependence on specific product lines
- Potential for product recalls or safety concerns
- High selling and marketing expenses
Opportunities
- Expanding into emerging markets
- Developing new minimally invasive surgical technologies
- Acquiring smaller, innovative companies
- Forming strategic partnerships with hospitals and healthcare systems
- Increasing focus on digital surgery solutions
Threats
- Intense competition from larger medical device companies
- Price pressures from healthcare providers
- Changes in healthcare regulations
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Stryker (SYK)
- Smith & Nephew (SNN)
Competitive Landscape
CONMED competes in a highly competitive market. Its strengths lie in its focused product portfolio and strong customer relationships. Weaknesses include its smaller size compared to larger competitors. To effectively compete, CONMED needs to continue innovating and expanding its geographic reach.
Major Acquisitions
Biorez, Inc.
- Year: 2022
- Acquisition Price (USD millions): 85
- Strategic Rationale: Acquired to add BioRez's BioBrace Implant to CONMED's sports medicine portfolio which enhances its existing offerings in sports medicine and soft tissue repair.
Growth Trajectory and Initiatives
Historical Growth: CONMED has experienced moderate growth over the past several years, driven by organic sales increases and strategic acquisitions.
Future Projections: Analysts project continued revenue growth for CONMED, driven by increasing demand for minimally invasive surgical procedures and the introduction of new products.
Recent Initiatives: Recent initiatives include investments in R&D, expansion into new geographic markets, and acquisitions of complementary businesses.
Summary
CONMED is a mid-sized medical technology company with a strong presence in orthopedics and general surgery. The company exhibits steady revenue growth, driven by a diverse product portfolio and strategic acquisitions. However, it faces intense competition and needs to continue innovating and expanding its market reach. While not paying dividends, the company's growth potential could offer shareholder returns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CONMED Corporation
Exchange NYSE | Headquaters Largo, FL, United States | ||
IPO Launch date 1987-07-23 | President, CEO & Director Mr. Patrick J. Beyer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3900 | Website https://www.conmed.com |
Full time employees 3900 | Website https://www.conmed.com | ||
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.